Login to Your Account

MedImmune In-Licenses New Inflammatory Disease Target

By Aaron Lorenzo

Friday, December 29, 2006
MedImmune Inc. acquired rights to a target for certain inflammatory diseases from Japan Tobacco (JT) Inc., with a lead compound the deal's centerpiece. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription